Cumberland Pharmaceuticals (CPIX) risk factors
Item 1A of every Cumberland Pharmaceuticals Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors56 risks5 new2 dropped5 reworded
New disclosures detail reliance on Talicia Holding for Talicia manufacturing and emerging regulations for artificial intelligence in drug development. Pricing pressure risks were updated to incorporate the Trump Administration's drug pricing executive orders.
Filed Mar 09, 2026 - FY2024 10-K risk factors53 risks
The business relies entirely on third-party manufacturers and suppliers for its six core brands and product candidates. Growth depends heavily on successful acquisitions and commercialization of unapproved candidates like ifetroban. Operations face intense pricing pressure and competition from generic equivalents and consolidated distributors.
Filed Mar 07, 2025